Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

McGovern A, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2017 Apr;8(2):355-363. doi: 10.1007/s13300-017-0229-8. Epub 2017 Jan 30.

2.

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.

McGovern A, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2017 Apr;8(2):365-376. doi: 10.1007/s13300-017-0254-7. Epub 2017 Mar 21.

3.

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol.

Hinton W, Feher MD, Munro N, de Lusignan S.

Diabetes Ther. 2019 Jun;10(3):1163-1170. doi: 10.1007/s13300-019-0620-8. Epub 2019 Apr 30.

4.

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.

Hinton W, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2018 Jun;9(3):1397-1402. doi: 10.1007/s13300-018-0390-8. Epub 2018 Mar 31.

5.

Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.

Naing S, Poliyedath A, Khandelwal S, Sigala T.

Postgrad Med. 2016 Nov;128(8):822-827. Epub 2016 Oct 25. Review.

PMID:
27701934
6.

SGLT2 inhibitors and cardiovascular outcomes: Do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.

Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E.

Curr Cardiol Rev. 2019 Jul 29. doi: 10.2174/1573403X15666190730094215. [Epub ahead of print]

PMID:
31362691
7.

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

Cavaiola TS, Pettus J.

Diabetes Metab Syndr Obes. 2018 Apr 12;11:133-148. doi: 10.2147/DMSO.S154602. eCollection 2018. Review.

8.

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.

Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators.

Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8.

9.

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.

Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. Review.

PMID:
27470878
10.

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Oral EA.

Drugs Context. 2016 Sep 2;5:212299. doi: 10.7573/dic.212299. eCollection 2016. Review.

11.

Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.

Satoh H.

Diabetol Int. 2018 Aug 14;9(4):212-214. doi: 10.1007/s13340-018-0367-x. eCollection 2018 Oct.

12.

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.

Gallwitz B.

Eur Endocrinol. 2018 Apr;14(1):17-23. doi: 10.17925/EE.2018.14.1.17. Epub 2018 Apr 18. Review.

13.

EMPA-REG OUTCOME: The Endocrinologist's Point of View.

Perreault L.

Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005.

14.

Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.

Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V.

Adv Ther. 2019 Oct;36(10):2895-2909. doi: 10.1007/s12325-019-01043-z. Epub 2019 Aug 13.

PMID:
31410779
15.

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

Ampudia-Blasco FJ, Romera I, Ariño B, Gomis R.

Int J Gen Med. 2017 Jan 13;10:23-26. doi: 10.2147/IJGM.S115566. eCollection 2017.

16.

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.

Rastogi A, Bhansali A.

Diabetes Ther. 2017 Dec;8(6):1245-1251. doi: 10.1007/s13300-017-0320-1. Epub 2017 Oct 26. Review.

17.

Cardio-renal protection with empagliflozin.

MacIsaac RJ, Jerums G, Ekinci EI.

Ann Transl Med. 2016 Oct;4(20):409.

18.

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.

Schernthaner G, Drexel H, Moshkovich E, Zilaitiene B, Martinka E, Czupryniak L, Várkonyi T, Janež A, Ducena K, Lalić K, Tankova T, Prázný M, Smirčić Duvnjak L, Sukhareva O, Sourij H.

BMC Endocr Disord. 2019 Jun 17;19(1):64. doi: 10.1186/s12902-019-0387-y.

19.

Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.

Suissa S.

Diabetes Care. 2018 Feb;41(2):219-223. doi: 10.2337/dc17-1059.

PMID:
29358464
20.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.

Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5.

PMID:
31495651

Supplemental Content

Support Center